Marcia Sellos-Moura

Title: A Remarkable Journey of Innovation: Marcia Sellos-Moura

Introduction

Marcia Sellos-Moura, an innovative inventor based in West Newbury, MA, has made significant contributions in the field of enzyme therapy for treating homocystinuria. With a portfolio of five patents, her work demonstrates a strong commitment to advancing medical science through innovative solutions.

Latest Patents

Among her latest patents, Marcia has developed a formulation for a drug product comprising a PEGylated cystathionine beta synthase (CBS) protein, which is instrumental in the treatment of homocystinuria. This disclosure provides specific dosages and dosing regimens aimed at reducing homocysteine levels and increasing cysteine and cystathionine in patients in need. Moreover, she has devised a method for PEGylating a human truncated cystathionine β-synthase protein, known as htCBS C15S. This method includes the use of NHS ester PEG molecules of various sizes to optimize enzyme replacement therapy and ensure effective treatment for individuals with homocystinuria.

Career Highlights

Marcia has worked with esteemed institutions such as the University of Colorado and Travere Therapeutics, based in Switzerland. Her experience in these organizations has enriched her expertise and contributed to her extensive research in enzyme therapy.

Collaborations

Throughout her career, Marcia has collaborated with fellow researchers like Tomas Majtan and Erez Bublil. These collaborations have fostered an environment of shared knowledge and innovation, furthering advancements in enzyme replacement therapies.

Conclusion

Marcia Sellos-Moura stands out as a pioneering inventor dedicated to improving healthcare outcomes for individuals affected by homocystinuria. Her groundbreaking inventions and collaborations highlight her role as a leader in the field of enzyme therapy, showcasing her unwavering commitment to innovation and the betterment of patient care.